日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Allogeneic RPE cell suspension manufactured at scale demonstrating preclinical safety and efficacy led to IND approval.

大规模生产的同种异体 RPE 细胞悬液证明了其临床前安全性和有效性,从而获得了 IND 批准

Soundararajan Lalitha, Surendran Harshini, Patlolla Niharika, Battu Rajani, Stoddard Jonathan, Arrizabalaga Sebastian, Liu Zengping, Lingam Gopal, Su Xinyi, Ryals Renee C, Pal Rajarshi